##1. Copper‑induced cell death (cuproptosis) and the metabolic Achilles' heel of colorectal cancer (CRC) CRC cells tend to accumulate excess copper (Cu) to support tumor growth, a phenotype closely linked to overexpression of the mitochondrial metabolic enzyme DLAT (dihydrolipoamide S‑acetyltransferase). Cuproptosis occurs when accumulated copper triggers lipoylation of DLAT protein, forming toxic aggregates that devastate mitochondrial function. However, CRC cells possess resistance mechanisms that tolerate high copper concentrations, making the identification of a molecular trigger capable of forcibly unleashing cuproptosis a central challenge for precision oncology.

##2. Lactylation of NAT10: Convergence of a metabolic by‑product and an RNA‑modifying enzyme The investigators discovered that treatment with Elesclomol induces a rapid surge in lactyl‑modification of the NAT10 protein within CRC cells. NAT10 catalyzes the N4‑acetylcytidine (ac4C) modification on RNA, and lactylation dramatically amplifies its enzymatic activity. This finding suggests that intracellular lactate metabolism functions not merely as an energy source but as an epitranscriptomic signal that modulates RNA‑modifying enzymes to reprogram the fate of specific genes.

##3. The ac4C‑DLAT axis and a positive feedback loop: Accelerating cancer cell death Activated NAT10 installs ac4C marks on defined regions of DLAT mRNA, protecting the transcript from degradation and enhancing its stability. Consequently, DLAT protein accumulates to supraphysiological levels and complexes with copper introduced by Elesclomol, provoking a robust cuproptotic response. Intriguingly, the excess DLAT further stimulates metabolic pathways that promote additional NAT10 lactylation, establishing a positive feedback loop that acts as a decisive engine driving cancer cells rapidly into an irreversible death state.

##4. A new therapeutic paradigm linking epitranscriptomics, metabolism, and metal‑dependent cell death The significance of this work lies in its comprehensive delineation of three previously disconnected domains: RNA ac4C modification, post‑translational lactylation of proteins, and copper‑dependent cell death. This integrated strategy diverges from conventional DNA‑targeted agents or metabolic inhibitors by converting the metabolic hallmarks of CRC—elevated lactate and copper levels—into lethal weapons against the tumor. Accordingly, combination regimens that modulate lactylation together with copper ionophores are poised to become a powerful next‑generation standard for treating refractory colorectal cancer.